Aprea Therapeutics
Clinical trials sponsored by Aprea Therapeutics, explained in plain language.
A clinical-stage biopharmaceutical company developing cancer therapies targeting p53 mutations.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for advanced cancer: APR-1051 enters first human trial Results expected Jun 2027 (estimated)